Workflow
海尔生物(688139) - 2021 Q1 - 季度财报

Financial Performance - Net profit attributable to shareholders increased by 506.02% to CNY 419,839,546.33 year-on-year[18] - Operating revenue reached CNY 413,627,238.36, representing a year-on-year growth of 55.01%[18] - Total profit amounted to CNY 476,851,880.04, marking a 508.51% increase from CNY 78,363,687.16, driven by growth in operating profit and investment income[39] - The company reported a total comprehensive income of ¥421,148,279.46 for Q1 2021, compared to ¥71,323,889.74 in Q1 2020, an increase of 493%[62] - Basic and diluted earnings per share both stood at CNY 1.32, reflecting a 500.00% increase from CNY 0.22 in the previous year[41] Revenue Growth - Revenue from the vaccine safety segment grew by 107.37%, while blood safety segment revenue surged by 263.53%[20] - Domestic market revenue increased by 48.01%, with IoT solution sales rising by 148.49%[21] - Overseas market revenue grew by 81.16%, with overseas distribution revenue up by 91.32%[22] Cash Flow and Liquidity - Cash flow from operating activities increased by 186.64% to CNY 124,170,918.10 compared to the same period last year[18] - The company reported a net cash flow from operating activities of CNY 124,170,918.10, up 186.64% from CNY 43,320,200.01, attributed to increased cash receipts from sales of goods and services[41] - Cash and cash equivalents decreased by 41.64% to ¥1,078,851,603.37 from ¥1,848,671,180.63, mainly due to investments in financial products[36] Assets and Liabilities - Total assets increased by 15.46% to CNY 4,551,948,540.71 compared to the end of the previous year[18] - Current liabilities rose to CNY 1,237,938,191.13 from CNY 1,044,354,545.25, an increase of about 18.5%[49] - The total liabilities increased to CNY 1,356,161,635.71 from CNY 1,158,084,744.73, reflecting a growth of approximately 17.1%[51] - The company's equity attributable to shareholders rose to CNY 3,186,802,247.17 from CNY 2,775,877,783.68, reflecting an increase of about 14.8%[51] Research and Development - R&D investment accounted for 9.99% of operating revenue, a slight increase of 0.10 percentage points[20] - Research and development expenses increased to CNY 41,339,082.29, a rise of 56.60% from CNY 26,398,022.90, mainly due to increased amortization of intangible assets[39] Shareholder Information - The number of shareholders reached 10,035, with the top ten shareholders holding a significant portion of shares[30] - The largest shareholder, Qingdao Haier Biomedical Holdings, holds 31.73% of shares, totaling 100,591,463 shares[30] Investment Income - The company recorded investment income of CNY 377,446,127.41, a staggering increase of 2,255.28% compared to CNY 16,025,552.92, primarily from government subsidies related to the disposal of joint ventures[39] - The company reported a significant increase in investment income, reaching approximately ¥319.84 million in Q1 2021, compared to ¥13.97 million in Q1 2020[67] Financial Expenses - The company reported a significant decrease in financial expenses, with interest expenses dropping by 80.68% to CNY 1,670,285.47, primarily due to a reduction in deposits[39] - The company’s financial expenses showed a reduction, with interest income of approximately ¥1.22 million in Q1 2021, down from ¥8.45 million in Q1 2020[67] Market Strategy - The company plans to continue expanding its market presence and investing in new technologies to drive future growth, although specific figures were not disclosed in the report[75]